SCYNEXIS - SCYX Earnings per one share for the last 12 months

Official company branding of SCYNEXIS Inc (SCYX)

The price history of SCYNEXIS, Inc. (SCYX) shares on the GURU.Markets platform demonstrates EPS TTM dynamics, which currently stand at 72.20. Growth for SCYNEXIS, Inc. (SCYX) is driven by Brexafemme sales, partner payments, and new tests against hospital-acquired pathogens. Patent protection ensures pricing power, although profits remain dependent on insurance reimbursements. This enables the brand to build a resistance-fighting network by introducing unique antifungal agents into medicine.

SCYNEXIS (SCYX): Net earnings per share (EPS TTM) from 02/11/2024 to 11/12/2026

Scynexis - analytical breakdowns and key metrics (SCYX)

- share price and consensus valuation forecast:
Share Price SCYNEXIS, Inc.|SCYX - Analyst Consensus Forecast
- issuer market value details:
Market Valuation SCYNEXIS Inc|SCYX - Enterprise Value
- book capitalization information:
Net Asset Value per Share SCYNEXIS|SCYX - Book Capitalization|Market Cap to Net Assets Ratio scynexis.com|SCYX - Cumulative Company Assets
- company total debt and liquidity indicators:
Aggregate Debt to Capital SCYNEXIS, Inc.|SCYX - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient SCYNEXIS, Inc.|SCYX - Company Debts|Debts to Book Value SCYNEXIS Inc|SCYX - Company Long-Term Debt|Company Short-Term Indebtedness SCYNEXIS|Interim Coverage Ratio scynexis.com
- net income and valuation ratios data:
SCYX - Company Net Income|Company Profit Forecast SCYNEXIS, Inc.|SCYX - P/E Multiple|Projected Price to Earnings SCYNEXIS, Inc.|SCYX - Price/Earnings to Growth Multiple|Company Value to EBITDA SCYNEXIS Inc|SCYX - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months SCYNEXIS|SCYX - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months scynexis.com|SCYX - Net earnings per share growth this year|Projected earnings per share growth rate for next year SCYNEXIS, Inc.
Initial company analysis:SCYX, SCYNEXIS
Manufactured products of SCYNEXIS

When selecting assets with a high margin of safety, the dynamics of net earnings per share, which reflect real capital efficiency, are critically important. Analyzing the year-over-year change in EPS (TTM) allows for an assessment of the resilience of SCYNEXIS, Inc. (SCYX) to borrowing costs and market pressure, which is particularly significant during the implementation of costly antifungal developments in collaboration with GSK and other global partners.

Competitor analysis

SMMT (summittxinc.com) - Earnings per share for the last 12 months|MRNA: Net earnings per share (EPS TTM)|Earnings per one share for the last 12 months PCVX (Vaxcyte Inc)|TARS (Tarsus Pharma) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months CorMedix Therapeutics CRMD|Net earnings per share (EPS TTM) MCRB|Net earnings per share for the last 12 months sperotherapeutics.com SPRO|AN2 Therapeutics - Net earnings per share for the last 12 months|Earnings per share for the last four quarters PYPD (PolyPid Ltd)|YS Biopharma - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters Iterum Therapeutics plc ITRM|biomx.com (PHGE) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Soligenix (SNGX)|Earnings per share for the last twelve months 60 Degrees Pharmaceuticals Inc.|Earnings per share for the last 12 months OGEN (Oragenics Inc.)|Earnings per share for the last twelve months OpGen Corp (OPGN)